Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide
Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide. PLOS ONE 2012, 7: e30479. PMID: 22279595, PMCID: PMC3261206, DOI: 10.1371/journal.pone.0030479.Peer-Reviewed Original ResearchMeSH KeywordsAdamantaneAntitubercular AgentsDiarylquinolinesDrug MonitoringDrug Therapy, CombinationEthylenediaminesExtensively Drug-Resistant TuberculosisHumansMicrobial Sensitivity TestsMycobacterium tuberculosisNitroimidazolesOxazolidinonesPyrazinamideQuinolinesReproducibility of ResultsTime FactorsConceptsPNU-100480Whole blood culturesPA-824Blood culturesWhole-blood bactericidal activityBactericidal activityStandard TB therapyDihydroxy vitamin DIntracellular M. tuberculosisBlood bactericidal activityCumulative activityPZA-resistant strainsHigh therapeutic concentrationsActive regimensTB regimensNew regimensTB therapyVitamin DOral dosingTherapeutic concentrationsDrug combinationsPharmacokinetic dataRegimensIndividual drugsTMC207